Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
73 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
- Macquarie University Hospital
North Ryde, New South Wales, Australia
- Royal Brisbane & Women S Hospital
Herston, Queensland, Australia
- Landeskrankenhaus Salzburg
Salzburg, Austria
- Allgemeines Krankenhaus Der Stadt Wien
Vienna, Austria
- Juravinski Cancer Center Hamilton Health Sciences
Hamilton, Ontario, Canada
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Chu de Quebec-Universite Laval-Hotel Dieu de Quebec
Québec, Quebec, Canada
- Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz
Miskolc, Hungary
- Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet
Szolnok, Hungary
- Istituto Europeo Di Oncologia
Milan, Italy
- Irrcs Instituto Clinico Humanitas
Rozzano, Italy
- National Cancer Center Hospital East
Kashiwa, Chiba, Japan
- Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
- Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
- Miyagi Cancer Center
Natori-shi, Miyagi, Japan
- Tohoku University Hospital
Sendai, Miyagi, Japan
- Hyogo Cancer Center
Akashi, Japan
- Kyushu University Hospital
Fukuoka, Japan
- Hiroshima University Hospital
Hiroshima, Japan
- Hokkaido University Hospital
Hokkaido, Japan
- Kobe City Medical Center General Hospital
Kobe, Japan
- Saitama Cancer Center
Saitama, Japan
- Kindai University Hospital
Sayama, Japan
- Shizuoka Cancer Center Hospital and Research Institute
Shizuoka, Japan
- the Cancer Institute Hospital of Jfcr
Tokyo, Japan
- Mazowiecki Szpital Onkologiczny
Wieliszew, Masovian Voivodeship, Poland
- Przychodnia Lekarska Komed
Konin, Poland
- Zachodniopomorskie Centrum Onkologii
Szczecin, Poland
- Inst. Portugues de Oncologia de Coimbra Frencisco Gentil Epe
Coimbra, Portugal
- Centro Hospitalar Lisboa Norte Epe - Hospital de Santa Maria
Lisbon, Portugal
- Inst. Portugues de Oncologia de Lisboa Francisco Gentil Epe
Lisbon, Portugal
- Inst. Portugues de Oncologia de Porto Francisco Gentil Epe
Porto, Portugal
- Asan Medical Center
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Severance Hospital Yonsei University Health System
Seoul, South Korea
- Hospital Germans Trias I Pujol. Ico de Badalona
Badalona, Spain
- Hospital General Universitari Vall D Hebron
Barcelona, Spain
- Hospital Infanta Cristina
Madrid, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Dec 2017
- Primary completion
- 19 Jul 2018
- Completion
- 30 Oct 2025
- Last update posted
- 3 Dec 2025
- Registered enrollment
- 89
- Registry id
- NCT03358472
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.